Skin aging, the skin barrier, skin disease and aesthetic treatments.
In a phase 1 study published Oct. 27, 2026, in the Aesthetic Surgery Journal, giving trenibotulinumtoxinE, a fast-acting type E toxin, and then onabotulinumtoxinA 30 days later for frown lines raised no…
In a phase 3 trial published Oct. 24, 2026, in Aesthetic Surgery Journal, 60.0% of adults treated with trenibotulinumtoxinE met a strict frown-line goal at day 7 vs. 0.6% with placebo; the…
A systematic review of nineteen studies with 4375 patients, published Oct. 14, 2026, in the American Journal of Clinical Dermatology, found that tapering targeted eczema drugs often kept disease controlled better than…
A UK study published Oct. 30, 2026, in the British Journal of Dermatology compared 320,220 people with psoriasis with 1,706,424 matched people and found links with conditions across the body, including liver…
A systematic review of 10 observational studies found that a median of 47.8% of people with nummular eczema, which causes coin-shaped itchy patches, tested positive for at least one contact allergen, with…
In a study of 77 people with mucous membrane pemphigoid affecting several body sites, published Oct. 28, 2026, in JAMA Dermatology, 45% reached complete remission at every site at once, after a…
A meta-analysis of thirteen studies with more than 500,000 people, published Oct. 28, 2026, in Dermatologic Surgery, found that Mohs surgery for melanoma was linked to similar or better long-term survival than…
In a randomized trial, a hyaluronic acid lip filler with lidocaine improved lip fullness in 91.1% of treated people at 8 weeks and was not inferior to an approved filler. About half…
A study of eighty-three patients published Oct. 26, 2026, in Dermatologic Surgery found that local surgical removal of hidradenitis suppurativa lesions lowered average pain from 6.9 to 0.9 on a visual pain…
Joint guidelines from the American Academy of Dermatology and the Hidradenitis Suppurativa Foundation, published Oct. 20, 2026, make 37 recommendations, with strong support for four biologic drugs and for checking pain at…
A Danish nationwide study published Oct. 3, 2026, found that 8.2% of people with hidradenitis suppurativa started a GLP-1 drug vs. 5.7% with psoriasis and 3.2% of controls; HS treatments fell afterward,…
In 157,966 US adults with atopic dermatitis, using a targeted therapy, almost always dupilumab, was linked to 1.6 points lower probability of hospitalization and 1.7 points lower probability of emergency visits, but…
A meta-analysis published Oct. 16, 2026, in BioDrugs found that 2.17% of people treated with biologics for psoriasis developed eczema-like reactions, most often with IL-17 inhibitors and least with IL-23 inhibitors.
In a sham-controlled trial published Oct. 14, 2026, in JAMA Dermatology, 56.9% of people with rosacea who pressed a seed taped on a specific spot of the ear reached clear or almost…
A large records study published in October 2026 in Experimental Dermatology found that people with eczema treated with dupilumab didn't have a higher two-year risk of psoriasis than those on steroid creams,…
